Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Amortization of Deferred Charges (2022 - 2025)

Arcutis Biotherapeutics (ARQT) has 4 years of Amortization of Deferred Charges data on record, last reported at $461000.0 in Q4 2025.

  • For Q4 2025, Amortization of Deferred Charges fell 82.24% year-over-year to $461000.0; the TTM value through Dec 2025 reached $1.8 million, down 67.51%, while the annual FY2025 figure was $1.8 million, 67.51% down from the prior year.
  • Amortization of Deferred Charges reached $461000.0 in Q4 2025 per ARQT's latest filing, up from $449000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $2.6 million in Q4 2024 and bottomed at $392000.0 in Q1 2022.
  • Average Amortization of Deferred Charges over 4 years is $862250.0, with a median of $898000.0 recorded in 2022.
  • Peak YoY movement for Amortization of Deferred Charges: skyrocketed 155.41% in 2024, then tumbled 82.24% in 2025.
  • A 4-year view of Amortization of Deferred Charges shows it stood at $1.0 million in 2022, then changed by 0.0% to $1.0 million in 2023, then soared by 155.41% to $2.6 million in 2024, then crashed by 82.24% to $461000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Amortization of Deferred Charges were $461000.0 in Q4 2025, $449000.0 in Q3 2025, and $431000.0 in Q2 2025.